What are the DIFFERENCES between INFLUENZA and SARS-CoV-2 in terms of MUTATION rates and
why are they VERY DIFFERENT VIRUSES ?
Influenza and SARS-CoV-2 differ in mutation rates due to their genetic mixing processes: reassortment and recombination.
2) REASSORTMENT occurs when two viruses infect the same cell and exchange RNA segments, generating new strains. This is typical for segmented viruses like influenza.
RECOMBINATION, which occurs in viruses with single, non-segmented genomes like SARS-CoV-2 ...
3) ...involves the simpler exchange of genetic material during replication. As a result, recombination with SARS-COV-2 allows for quicker generation of genetic diversity, while reassortment with Influenza requires a more complex mixing of entire genome segments.
4) I used this study to illustrate my point because the subject covered here
is to test four dimensionality reduction techniques on simulated viral populations as well as real-world data from seasonal influenza A/ H3N2 and SARS-CoV-2.biorxiv.org/content/10.110…
5) They demonstrate that simple dimensionality reduction methods can effectively capture biologically-relevant information about the evolution and relationships of human pathogenic viruses, even for viruses that violate assumptions of traditional phylogenetic approaches.
Thanks
• • •
Missing some Tweet in this thread? You can try to
force a refresh
2) The study suggests that the mutations in SARS-CoV-2 mutant spectra arise through a stochastic process, rather than being primarily driven by immune pressure.
3) A few key points from the text:
- The text states that "Random events with biological consequences abound at all stages of the infectious cycle of viruses." This indicates that the mutations arise stochastically, rather than being directed by ...
EVOLUTION of SARS-COV-2 :
STOCHASTIC processes or IMMUNE evasion ?
(2nd part)
Before delving deeper into the stochastic evolution of the virus, a study to highlight the role of immune evasion in the variants evolutionary process.
2) "Evolution of new variants of SARS-COV-2 during the pandemic: mutation limited or selection limited?"
The paper examines how new variants of SARS-CoV-2 emerged during the COVID-19 pandemic. biorxiv.org/content/10.110…
3) It looks at whether the rise of new variants was limited by the ability to mutate (mutation-limited) or by the conditions that allow them to spread (selection-limited).
The analysis shows the rise of new variants was selection-limited, not mutation-limited.
RAPID TESTS (RDT) FALSE NEGATIVES, NOT DUE to VIRAL EVOLUTION, but likely ISSUES, with HOW PEOPLE were USING the self-tests, not problems with the tests themselves.
2) This study used a participatory surveillance program to monitor how well SARS-CoV-2 rapid tests (RDTs) were working in the Netherlands. They found that even when people tested negative on the RDTs, many still had high levels of the virus when tested by ...
3) ...the more accurate PCR method. However, this was not due to the virus evolving to avoid detection - when the RDT-negative samples were retested in the lab, they all tested positive.
During the acute phase of a COVID-19 INFECTION, individuals EXPERIENCE significant AGE ACCELERATION of up to 24.47 YEARS due to disrupted homeostasis 😨😨😨
2) The study developed a highly accurate transcriptomic clock to predict chronological age using 47 genes primarily involved in lymphoid immune function. This clock was validated across multiple healthy cohorts.
3) Remarkably, the transcriptomic age of COVID-19 patients showed dramatic acceleration of up to 24.47 years during acute infection. This age acceleration correlated with markers of inflammation, such as C-reactive protein and immune cell counts.
2) This study examined how COVID-19 vaccination affected the spread of the virus in the UK during 2021. The researchers used a mathematical model to analyze data on vaccination rates, circulating virus variants, and the reproduction number (R) across different local areas.
3) The key findings are:
- One dose of vaccine reduced virus transmission by 39%, and three doses by 49%, but two doses had little effect. This was likely due to the rise of the more contagious Delta variant during the two-dose rollout.